Authors
John M. Crespo, Lauren Shaw, Isabella Pargiolas, and Dr. Daniel J Powell Jr.
Abstract
Chimeric antigen receptor (CAR) T-cell therapy has been a promising strategy to target hematological malignancies and potentially, solid tumors. Response rates are greater than 80% in certain applications with FDA-approved products targeting B-cell antigens.
Universal Immune Receptors (UIRs) are a strategy to improve control, with the addition of targeting multiple antigens by modifying the extracellular element of the CAR.
Both approaches currently rely on ex vivo engineering of T cells. In vivo generation of CAR-or UIR- expressing T cells will further improve accessibility.
Hypothesis: Usage of a targeted lentivirus that encodes for Universal Immune Receptors will improve the accessibility of CART therapy.